重组人红细胞生成素治疗肿瘤相关性贫血的研究

Recombinant Human Erythropoietin for the Treatment of Cancer Related Anemia

目的：观察促红细胞生成素（EPO）在治疗肿瘤相关性贫血中的疗效和毒副作用。方法：对2007年9月-2007年11月期间我院收治的33例患肿瘤相关性贫血患者使用促红细胞生成素治疗,并观察患者的行为状况、血色素水平以及副反应。结果：33例肿瘤相关性贫血患者在EPO治疗前后的血色素水平有显著升高（88.6g/L±19.3g/L vs 103.5g/L±21.3g/L,P〈0.01）,EPO治疗后的患者的行为状况评分也有显著性改善。治疗期间有5例患者出现血色素下降,其中输血1例。有9例患者在化疗前或同时使用EPO,血色素由93.7g/L±11.2 g/L升高为100.3g/L±16.8 g/L,P〈0.05）。33例患者无血栓形成,血压升高和过敏。结论：促红细胞生成素能提高肿瘤相关性贫血患者的血色素水平和行为状况评分,而且安全性高。EPO可能还有预防化疗导致贫血的作用。

Objective： To study the treatment of cancer related anemia by the recombinant human erythropoietin. Methods： During September to November in 2007, the recombinant erythropeietin was used in 33 patients and the KPS score, hemogram and side reaction were observed. Results： After treaed by EPO, the haemoglobin level of patients was much higher than in pretreated period （88.6g/L ± 19.3g/L vs 103.5g/L ＋ 21.3g/L, P 〈 0.01 ）. In our research, 9 patients were treated by EPO before or during the chemotherapy period and the change of haemoglobin level was significant （93.7g/L ± 11.2g/L increased to 100.3g/L±16.8g/L, P 〈 0. 05）. No thrombosis, hypertension and allergy was observed in these 33 eases. Conclusion： EPO can improve haemoglobin level and KPS in patients who get cancer related anemia and may prevent chemotherapy related anemia.